Tardive Dyskinesia - Articles and news items

FDA approves first drug to treat tardive dyskinesia

Industry news / 12 April 2017 / Niamh Marriott, Junior Editor

The US Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition.   Tardive dyskinesia is a neurological disorder characterised by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue […]

Neurocrine’s Tardive Dyskinesia drug application accepted for FDA priority review

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for Neurocrine Biosciences‘ Ingrezzatm (valbenazine) for the treatment of tardive dyskinesia. The application has been given a prescription drug user fee act (PDUFA) target action date of April 11, 2017. A Priority Review designation accelerates the FDA review […]

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+